They'd have to sell off all the e-detailing assets and focus exclusively on diagnostics. Then, they'd have to hire a veteran diagnostics CEO. I've got investments in micro cap diagnostics, but I'd to research whether what PDII has bought is competitive or not. One thing's for sure: there's no way that Nancy Lurker can run whatever emerges from the ashes.
Well, no exactly. If the new CFO announces asset sales and other company-saving measures, perhaps it won't continue to slide, but it's still overvalued right now.
I think Lurker is probably a figurehead at this point. I don't know when her contract is up, but there's no way she'll be renewed.
No doubt. I'm sure Sperzel would love to come on the call with the waiver in hand. He's gambled on sales/marketing spend, he's continuing to invest in complying with the new Syph algo, he's putting money into HCV. If the FDA crushes DPP HIV by refusing to waiver it or by asking for more data, that's going to effectively end CEMI's US operations.
All about the waiver now. We're nearly three weeks beyond Sperzel's target date. The market's clearly worried. I'm not worried, but I wouldn't be surprised to see bad news.
It would seem likely that the FDA indicated to Sperzel a decision by end of Q3, else he wouldn't have announced it publicly. Sperzel gambled that they'd get the waiver, which is why he broke with ALR on Stat-Pak and hired sales and marketing personnel. He must have been very confident. Is he still?
First, it was great that LS wasn't selling. Now, you're advising him to sell. Last week, you were droning on about how CEMI should focus on cervids or lord knows what. Are you scrambled in the head or clinically insane. It's hard to tell. Also, either you speak and write English as a second language or you're just borderline illiterate. Sad and disturbing, and a big negative for this board.
Agree about TRIB. As regards CEMI CLIA waiver, perhaps CEMI can get top FDA brass to look into matter of DPP HIV waiver delay. I think the argument is that, without DPP HIV revenues, CEMI really can't move forward on a DPP Ebola test. The company is just too small. That sort of thing.
CEMI should make the argument: if DPP is good enough for a POC Ebola test, why isn't it also for an HIV one? In fact, they should only commit to DPP Ebola after they've gotten the waiver for DPP HIV.
Is the FDA just taking its time? Has it asked for more data? This, more than the Ebola hoopla, is key to the future growth of this company. They've got sales reps sitting and waiting to move DPP HIV. They've spent money on marketing and PR, and yet they've got no product. Also, it's hard to justify spending on DPP product research for the US market if those products will struggle to get a CLIA waiver.
Neither TRIB (syphilis) nor ALR (Determine Combo) have gotten their CLIA waivers yet, either.
If you've got a large number of companies creating tests, ultimately that's not going to be good for any of them. The selling price of these tests will invariably be low. So, if US government agencies or other big donors aren't laying a big pile of cash on the table right now, I'd be reluctant to spend time and money on Ebola.
In fact, OSUR CEO was VERY noncommittal about his company's involvement. CEMI, OSUR and the rest aren't going to do this as a public service.
There are risks associated with involvement in such a project, not the least of which is financial risk. Funders had better be offering attractive terms to CEMI. CEMI has a limited research team, which is engaged in other projects. It would be hard to justify pulling them for Ebola, unless the amount of money was very substantial.
That's how long it's been since the Yale student researcher back from Liberia was admitted to hospital, and still no diagnosis. How badly do we need a rapid test. These quarantine, hazmat, isolation admissions run $1000 an hour.
Good find, he said reluctantly.
CEMI has been working with various agencies on DPP for several years now. There is absolutely no doubt that CEMI is involved. They have an oral fluid test which is in every way superior to OSUR's. I think it's prudent for CEMI not to toot its horn as regards Ebola. The fact that they wouldn't confirm or deny is a confirmation, in my view.
If the CDC and/or DOD doesn't have Mr. Esfandiari and DPP on the case, they are damn fools.